Company Overview - JiuZhiTang Co., Ltd. is located in Beijing and Changsha, established on May 12, 1999, and listed on June 28, 2000. The company specializes in the research, production, and sales of traditional Chinese medicine, biological pharmaceuticals, and cardiovascular drugs [2][3] - The revenue composition includes prescription drugs (50.27%), OTC products (46.11%), other products (2.50%), health products (0.92%), and other supplementary products (0.20%) [2] Financial Performance - For the first half of 2025, JiuZhiTang reported revenue of 1.265 billion yuan, a year-on-year decrease of 24.71%, and a net profit attributable to shareholders of 144 million yuan, down 29.71% year-on-year [2] - The company has distributed a total of 4.364 billion yuan in dividends since its A-share listing, with 935 million yuan distributed over the past three years [3] Stock Performance - As of August 27, JiuZhiTang's stock price was 12.00 yuan per share, with a market capitalization of 10.271 billion yuan. The stock has increased by 56.60% year-to-date [1] - The stock has seen a net outflow of 22.5743 million yuan in major funds, with significant trading activity reflected in the recent five-day (1.44% increase), twenty-day (5.36% increase), and sixty-day (16.62% increase) performance [1] Shareholder Information - As of June 30, 2025, the number of shareholders increased by 25.14% to 50,500, with an average of 13,739 circulating shares per shareholder, a decrease of 20.09% [2][3] - The top ten circulating shareholders include a new entrant, Qianhai Kaiyuan Stable Growth Mixed Fund, holding 1.996 million shares [3]
九芝堂跌2.04%,成交额2.20亿元,主力资金净流出2257.43万元